GenVec — Needham & Co. Second Annual Biotechnology Conference 2003
26 slides from GenVec's conference presentation, Jun 5, 2003
Slide 1: GenVec at Needham Second Annual Biotechnology Conference
GENVEC Needham & Co, Second Annual Biotechnology Conference June 5, 2003
Slide 2: Forward-Looking Statements
Forward-Looking Statements ‘The presentations made during this meeting and other statements by GenVec may include forward- looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the pending meraer with Diacrin, product candidates under development, futu
Slide 3: Merger: Additional Information
Merger: Additional Information Gene has fed registration statement withthe SEC under theSecuntes Act of 1933, which contains 2 srelianary joint pry satementlprospectus of GenVec and Dacia wih respect othe merger andthe paris also ‘el ile other relevant matenals wh the SEC. INVESTORS AND SECURITY HOL
Slide 4: Link to searchable text of slide shown above
Link to searchable text of slide shown above
Slide 5: SARS Vaccine: Using GenVec's Technology Platform
EES SARS Vaccine: Using GenVec’s Technology Platform * SARS poses a worldwide health threat * GenVec and NIH expand existing collaboration + Fast and flexible technology attributes
Slide 6: Multiple Product Opportunities
Multiple Product Opportunities TECHNOLOGY PLATFORM Core Expertise
Slide 7: Growing The Vaccine Business
Growing The Vaccine Business + New and expanded development partnerships VACCINES « Expand existing manufacturing capabilities + Develop new technology Fully funded and product opportunities through partnerships
Slide 8: Therapeutic Product Development
Therapeutic Product Development - commit internal resources + Oncology... Metra) - seek partners for Europe and Asia + Heart Diseas Telia) © - Fuso collaboration to develop + Macular Degeneration...AdPEDF second generation TNFerade’ - Form new partnerships - BIOBYPASS® Product Portfolio - AdPEDF
Slide 9: Technology for Therapeutics and Vaccines
Technology for Therapeutics and Vaccines Adenovector Insert DNA Insert DNA for therapeutic for antigenic protein protein Therapeutic Vaccine Candidate Candidate Locally Administered
Slide 10: TNFerade for Oncology
a ENV ES TNFerade™ for Oncology + Intratumoral delivery of TNFa to improve safety and effectiveness + Use with standard of care ~ Radiation , — Chemotherapy * Ongoing Phase II studies — Locally advanced pancreatic cancer — Non-metastatic esophageal cancer + Broad potential use for other cancers — Re
Slide 11: TNFerade Radiation Therapy: Phase I Summary
TNFerade"” Radiation Therapy: Ph | Summary Responses Minor Responses Complete Responses Tumor shrinkage demonstrated in 22 of 30 treated and evaluable patients (73% response rate ) Tumor Types Responding: + breast + rectal + melanoma + lung epatocellular *head/neck + colon + bladder + adrenal + bili
Slide 12: Phase I Study in Soft Tissue Sarcoma
a ENV ES Phase | Study in Soft Tissue Sarcoma * Well tolerated with no dose limiting toxicities + TNFerade plus radiation resulted in an overall objective tumor response rate of 85% (11 of 13 patients) + 100% objective response rate at highest dose of TNFerade™ (6/6) + Complete response in 2 of 13 p
Slide 13: Pancreatic Cancer - Patient Stratification
a ENE Pancreatic Cancer — Patient Stratification 30,000 Pancreatic patients Sov _— : Potential Surgical | | Locally Advanced Resection ‘Non-metastatic 6,000 12,000 — negative Goal: margins Improve 3,000 survival (S year survival $-20%)
Slide 14: Pancreatic Cancer: Preliminary Results
OO ad Pancreatic Cancer: Preliminary Results + 'TNFerade™ dose escalation phase ongoing « First 17 patients from initial two cohorts (4 x 10°, 4 x 10! pu) + Repeated intratumoral injections of TNFerade combined with continuous infusion 5-FU and radiation were well tolerated. + TNFerade™ administered
Slide 15: Ongoing Trial in Esophageal Cancer
a ENV ES Ongoing Trial in Esophageal Cancer + TNFerade™ dose escalation phase ongoing + Establish dose when used in combination with radiation therapy, fluorouracil and cis-platinum Dose Expected Status patients 4x10° pu 6 4/6 4x10? pu 6 0/6 4x10" pu 6 0/6
Slide 16: BIOBYPASS for Coronary Artery Disease (CAD)
BIOBYPASS’ for Sa cl Coronary Artery Disease (CAD) + Narrowing of coronary arteries results in poor blood flow + BIOBYPASS®is designed to stimulate new blood vessel formation, and improve blood flow * Positive Phase II data presented at November 2002 AHA Annual Meeting
Slide 17: Randomized, Controlled Phase II Study
Randomized, Controlled Phase II Study + Severe heart disease (“no option”) patients — BIOBYPASS® administered directly into the heart muscle * Significant clinical benefits — Exercised longer on treadmill — Exercised longer before EKG changes — Improved quality of life * Well tolerated — No evidence
Slide 18: Improved Ability to Exercise
Improved Ability to Exercise Time to Chest Pain Total Exercise Duration p=0.008 — p=0.002 peOoll = p=0.014 2 2 Z By Bioaveasse Bacon +—| a i L| | Weeks Post Treatment
Slide 19: BIOBYPASS for CAD
a ENV ES BIOBYPASS® for CAD + Feasibility of catheter-based delivery demonstrated + Form collaboration to advance clinical development + Meet with the FDA on trial design + Initiate randomized, placebo-controlled study using injection catheter
Slide 20: Age-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration (AMD) + Wet AMD - growth of tiny blood vessels under the retina that leak fluid, distorting vision and causing scarring. + Over 200,000 Americans have wet AMD treatments for AMD
Slide 21: AdPEDF to Treat AMD
OO a AdPEDF to Treat AMD + PEDF regulates abnormal blood vessel growth + Effective and well tolerated in preclinical studies + Ongoing Phase I trial in patients with wet AMD + Seeking development partner
Slide 22: Early Research in Hearing Loss
a ENV ES Early Research in Hearing Loss GenVee technology used to grow new hair follicles in inner ear cell of guinea pig. Potential use in hearing loss and Dales ares - Journal of Neuroscience June 2003
Slide 23: Proposed Merger of GenVec and Diacrin
ES Proposed Merger of GenVec and Diacrin + Announced + Expected closing 3Q03 April 15, 2003 ambled subject to shareholder ta pany) approval + Develop TNFerade™ + Expand vaccine business + Form product partners + Operating horizon into 2006 Diacrin + Strong elinieal pipeline + $43 million in cash as
Slide 24: GenVec Stand Alone Projections - 2003
OO a GenVec, Inc. Stand Alone Projections - 2003 + Anticipated Revenues - $10 million (existing contracts) Expected Cash Burn — 1H 2003: $10 million Restructuring Program announced in 2Q 2003 Expected Cash Burn — 2H 2003: $5 to $6 million Active partnering discussions around therapeutic products and
Slide 25: GenVec: Next Steps
a ENV ES GenVec: Next Steps + Establish dose and route of administration of TNFerade™ for randomized, controlled clinical trial(s) * Complete ongoing Phase I trial of AAPEDF + Establish partnerships to advance development of our therapeutic products * Advance vaccine candidates in all four programs
Slide 26: Link to searchable text of slide shown above
Link to searchable text of slide shown above Searchable text section of graphics shown above GENVEC [GRAPHIC] Needham & Co. Second Annual Biotechnology Conference June 5, 2003 GENVEC Forward-Looking Statements The presentations made during this meeting and other statements by GenVec may include forw
Genvec — Needham & Co. Second Annual Biotechnology Conference 2003 on 6ix